CL2011001848A1 - Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. - Google Patents
Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.Info
- Publication number
- CL2011001848A1 CL2011001848A1 CL2011001848A CL2011001848A CL2011001848A1 CL 2011001848 A1 CL2011001848 A1 CL 2011001848A1 CL 2011001848 A CL2011001848 A CL 2011001848A CL 2011001848 A CL2011001848 A CL 2011001848A CL 2011001848 A1 CL2011001848 A1 CL 2011001848A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- angiotensin
- hypertension
- pharmaceutical composition
- heart disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010020772 Hypertension Diseases 0.000 title abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 title 1
- 208000011775 arteriosclerosis disease Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000003614 peroxisome proliferator Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto derivado de pirimidina sustituida con actividad antagonista de angiotensina II; composición farmacéutica; útil para prevenir o tratar enfermedades circulatorias tales como hipertensión, enfermedad cardíaca, ateroesclerosis, enfermedad renal, apoplejía cerebral, hiperlipidemia, obesidad y/o diabetes, entre otras.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009020720 | 2009-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001848A1 true CL2011001848A1 (es) | 2012-02-03 |
Family
ID=42026435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001848A CL2011001848A1 (es) | 2009-01-30 | 2011-07-29 | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US8592431B2 (es) |
| EP (1) | EP2384327B1 (es) |
| JP (2) | JP4892649B1 (es) |
| KR (1) | KR20110113758A (es) |
| CN (2) | CN103788097B (es) |
| AR (1) | AR075344A1 (es) |
| AU (1) | AU2010208863A1 (es) |
| CA (1) | CA2750710C (es) |
| CL (1) | CL2011001848A1 (es) |
| CO (1) | CO6362011A2 (es) |
| CR (1) | CR20110463A (es) |
| CY (1) | CY1114530T1 (es) |
| DK (1) | DK2384327T3 (es) |
| DO (1) | DOP2011000249A (es) |
| EA (1) | EA019823B1 (es) |
| EC (1) | ECSP11011294A (es) |
| ES (1) | ES2433225T3 (es) |
| GE (1) | GEP20135961B (es) |
| HR (1) | HRP20131017T1 (es) |
| IL (1) | IL214283A0 (es) |
| MA (1) | MA33071B1 (es) |
| ME (1) | ME01621B (es) |
| MX (1) | MX2011008058A (es) |
| MY (1) | MY152946A (es) |
| NZ (1) | NZ594606A (es) |
| PE (1) | PE20120593A1 (es) |
| PL (1) | PL2384327T3 (es) |
| PT (1) | PT2384327E (es) |
| RS (1) | RS53012B (es) |
| SG (1) | SG173135A1 (es) |
| SI (1) | SI2384327T1 (es) |
| TN (1) | TN2011000368A1 (es) |
| TW (2) | TWI468410B (es) |
| UY (1) | UY32409A (es) |
| WO (1) | WO2010087515A1 (es) |
| ZA (1) | ZA201105867B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32409A (es) | 2009-01-30 | 2010-08-31 | Takeda Pharmaceutical | Compuesto de anillo fusionado y su uso |
| DK2655375T3 (en) | 2010-12-23 | 2015-03-09 | Sanofi Sa | PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF |
| CZ304252B6 (cs) * | 2011-04-11 | 2014-01-29 | Zentiva, K. S. | Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan |
| JP7042812B2 (ja) * | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| SG11202002632VA (en) | 2017-09-26 | 2020-04-29 | Ecolab Usa Inc | Acidic/anionic antimicrobial and virucidal compositions and uses thereof |
| SG11202011883RA (en) | 2018-05-31 | 2020-12-30 | Hua Medicine Shanghai Ltd | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN112745319B (zh) * | 2019-10-30 | 2022-06-17 | 中国科学院上海药物研究所 | 一类取代三环结构的化合物、其制备方法及用途 |
| CN114901072B (zh) | 2019-12-16 | 2024-12-17 | 埃科莱布美国股份有限公司 | 阴离子表面活性剂对杀病毒功效的影响 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472967A (en) | 1991-02-20 | 1995-12-05 | Synthelabo | 4-pyrimidinone derivatives their preparation and their application in therapy |
| FR2672892B1 (fr) * | 1991-02-20 | 1994-01-14 | Synthelabo | Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique. |
| TW251288B (es) * | 1991-06-27 | 1995-07-11 | Takeda Dharm Industry Co Ltd | |
| IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
| IT1250749B (it) | 1991-08-02 | 1995-04-21 | Luso Farmaco Inst | Composti eterociclici ad attivita' a ii antagonista |
| US5387747A (en) | 1992-02-24 | 1995-02-07 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present |
| US5389632A (en) | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
| FR2687677B1 (fr) * | 1992-02-24 | 1996-10-11 | Union Pharma Scient Appl | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| IT1263804B (it) | 1993-01-22 | 1996-09-03 | Luso Farmaco Inst | Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista |
| GB9406573D0 (en) | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
| DK0831910T3 (da) | 1995-06-07 | 2002-05-21 | Searle & Co | Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt |
| WO1996040256A1 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone |
| WO1996040258A2 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
| AU6039296A (en) | 1995-06-07 | 1996-12-30 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| SE0101579D0 (sv) | 2001-05-04 | 2001-05-04 | Astrazeneca Ab | New compounds |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
| US20050065184A1 (en) | 2003-08-29 | 2005-03-24 | Aaipharma Inc. | Method of reducing the risk of oxidative stress |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| WO2005118588A1 (ja) | 2004-06-02 | 2005-12-15 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
| US20050288272A1 (en) | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| MXPA06014448A (es) | 2004-06-23 | 2007-03-01 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema productor de endotelina endogena y antagonista del receptor at1. |
| EP1937254A2 (en) | 2005-07-27 | 2008-07-02 | Mor Research Applications Ltd. | Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology |
| WO2007053406A1 (en) | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
| WO2007051007A2 (en) | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
| US20080064871A1 (en) | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
| US20090012052A1 (en) | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
| CA2668725A1 (en) | 2006-11-09 | 2008-05-22 | Ore Pharmaceuticals Inc. | Breast cancer screening and treatment methods |
| JP2010510962A (ja) * | 2006-11-24 | 2010-04-08 | 武田薬品工業株式会社 | 複素単環化合物およびその用途 |
| EP2151440A4 (en) | 2007-05-21 | 2010-10-20 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
| WO2009039069A1 (en) | 2007-09-20 | 2009-03-26 | University Of Rochester | Method and compositions for treatment or prevention of inflammatory conditions |
| WO2009118292A1 (en) | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| EP2279009A4 (en) | 2008-05-05 | 2011-09-21 | Univ Rochester | METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE |
| UY32409A (es) * | 2009-01-30 | 2010-08-31 | Takeda Pharmaceutical | Compuesto de anillo fusionado y su uso |
-
2010
- 2010-01-29 UY UY0001032409A patent/UY32409A/es not_active Application Discontinuation
- 2010-01-29 EP EP10703532.1A patent/EP2384327B1/en active Active
- 2010-01-29 JP JP2011525329A patent/JP4892649B1/ja not_active Expired - Fee Related
- 2010-01-29 PE PE2011001418A patent/PE20120593A1/es not_active Application Discontinuation
- 2010-01-29 HR HRP20131017AT patent/HRP20131017T1/hr unknown
- 2010-01-29 MX MX2011008058A patent/MX2011008058A/es active IP Right Grant
- 2010-01-29 GE GEAP201012358A patent/GEP20135961B/en unknown
- 2010-01-29 MY MYPI2011003554 patent/MY152946A/en unknown
- 2010-01-29 AR ARP100100240A patent/AR075344A1/es unknown
- 2010-01-29 CN CN201310750040.3A patent/CN103788097B/zh not_active Expired - Fee Related
- 2010-01-29 SI SI201030403T patent/SI2384327T1/sl unknown
- 2010-01-29 US US13/146,989 patent/US8592431B2/en not_active Expired - Fee Related
- 2010-01-29 WO PCT/JP2010/051651 patent/WO2010087515A1/en not_active Ceased
- 2010-01-29 ES ES10703532T patent/ES2433225T3/es active Active
- 2010-01-29 PL PL10703532T patent/PL2384327T3/pl unknown
- 2010-01-29 SG SG2011053741A patent/SG173135A1/en unknown
- 2010-01-29 AU AU2010208863A patent/AU2010208863A1/en not_active Abandoned
- 2010-01-29 EA EA201101138A patent/EA019823B1/ru not_active IP Right Cessation
- 2010-01-29 NZ NZ594606A patent/NZ594606A/xx not_active IP Right Cessation
- 2010-01-29 DK DK10703532.1T patent/DK2384327T3/da active
- 2010-01-29 US US12/696,147 patent/US8283353B2/en not_active Expired - Fee Related
- 2010-01-29 CA CA2750710A patent/CA2750710C/en not_active Expired - Fee Related
- 2010-01-29 PT PT107035321T patent/PT2384327E/pt unknown
- 2010-01-29 TW TW99102537A patent/TWI468410B/zh not_active IP Right Cessation
- 2010-01-29 KR KR1020117020049A patent/KR20110113758A/ko not_active Withdrawn
- 2010-01-29 CN CN201080014441.7A patent/CN102369205B/zh not_active Expired - Fee Related
- 2010-01-29 ME MEP-2013-131A patent/ME01621B/me unknown
- 2010-01-29 MA MA34132A patent/MA33071B1/fr unknown
- 2010-01-29 TW TW103125956A patent/TW201444848A/zh unknown
- 2010-01-29 RS RS20130472A patent/RS53012B/sr unknown
-
2011
- 2011-06-30 JP JP2011146858A patent/JP5676379B2/ja not_active Expired - Fee Related
- 2011-07-25 IL IL214283A patent/IL214283A0/en unknown
- 2011-07-27 TN TN2011000368A patent/TN2011000368A1/fr unknown
- 2011-07-29 CL CL2011001848A patent/CL2011001848A1/es unknown
- 2011-07-29 DO DO2011000249A patent/DOP2011000249A/es unknown
- 2011-08-09 US US13/205,967 patent/US8921379B2/en not_active Expired - Fee Related
- 2011-08-11 ZA ZA2011/05867A patent/ZA201105867B/en unknown
- 2011-08-26 CR CR20110463A patent/CR20110463A/es unknown
- 2011-08-29 CO CO11109923A patent/CO6362011A2/es active IP Right Grant
- 2011-08-30 EC EC2011011294A patent/ECSP11011294A/es unknown
-
2013
- 2013-10-22 US US14/059,868 patent/US9115136B2/en not_active Expired - Fee Related
- 2013-10-25 CY CY20131100941T patent/CY1114530T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| CL2008003847A1 (es) | Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad. | |
| PE20120812A1 (es) | Compuestos vinil indazolilo | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| PE20141421A1 (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| UY32884A (es) | 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| CL2007003441A1 (es) | Compuestos derivados de 1,4-diazepam sustituido, antagonistas del receptor de orexina; composicion farmaceutica; y uso para el tratamiento o prevencion de un trastorno del sueno, para potenciar la calidad del sueno, y para tratar o controlar la obesi | |
| EA201300869A1 (ru) | Морфинановые соединения | |
| CL2011002989A1 (es) | Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros. | |
| EP2614860A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRY EYES | |
| EA200701705A1 (ru) | Антагонисты рецепторы глюкагона, получение и терапевтическое применение | |
| CL2008000905A1 (es) | Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena. | |
| CO6300953A2 (es) | Antagonistas del receptor mineralcorticoide y metodos de uso | |
| AR061271A1 (es) | Antagonistas de cgrp | |
| CL2011000071A1 (es) | Compuestos derivados de oxazolopirimidinas, antagonistas del receptor edg-1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades cardiovasculares, trombosis, aterosclerosis, hipertension, diabetes, enfermedades renales, respiratorias, inflamatorias y autoinmunes, entre otras. | |
| AR065714A1 (es) | Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida | |
| ECSP10010168A (es) | Benzotiazolas como moduladores del receptor de ghrelina | |
| EA201591123A1 (ru) | Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств | |
| UY31768A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre | |
| EA201070916A1 (ru) | Двойные фармакофоры - pde4-мускариновые антагонисты |